Loading..

Anavex Life Sciences Corp. (AVXL) Report Analysis

Corporate Events

Neutral

Anavex Life Sciences Corp. has filed a Shelf Re...

2022-06-10 00:00:00

Anavex Life Sciences Corp. has filed a Shelf Registration in the amount of $85.4 million. Security Name: Common Stock Securities Offered: ...

Neutral

BioToChina, CHBD, iDeals, ACCESS China Inc...

2022-06-08 14:40:00

BioToChina, CHBD, iDeals, ACCESS China Inc., BioAlps, Yafo Capital, Access China Biotech Forum, Jun 21, 2022 through Jun 24, 2022.

Neutral

Anavex Life Sciences Corp. Presents at Access C...

2022-06-08 00:00:00

Anavex Life Sciences Corp. Presents at Access China Biotech Forum, Jun-22-2022 11:00 AM.

Neutral

Anavex Life Sciences Corp. Presents at H.C. Wai...

2022-05-20 04:14:00

Anavex Life Sciences Corp. Presents at H.C. Wainwright Global Investment Conference 2022, May-25-2022 12:00 PM. Venue: Fontainebleau Miami Bea...

Neutral

Anavex Life Sciences Corp. to Report Q2, 2022 R...

2022-05-03 11:00:00

Anavex Life Sciences Corp. announced that they will report Q2, 2022 results on May 10, 2022

Neutral

Anavex Life Sciences Corp., Q2 2022 Earnings Ca...

2022-05-03 11:00:00

Anavex Life Sciences Corp., Q2 2022 Earnings Call, May 10, 2022

Neutral

Anavex Life Sciences Corp. Presents at Rett Syn...

2022-04-27 00:00:00

Anavex Life Sciences Corp. Presents at Rett Syndrome Scientific Symposium 2022, Apr-26-2022 . Speakers: Walter E. Kaufmann, Chief Scientific Officer.

Neutral

Anavex Life Sciences Corp. Presents at B. Riley...

2022-04-26 11:00:00

Anavex Life Sciences Corp. Presents at B. Riley Securities's 2022 Virtual Neurology & Ophthalmology Conference, Apr-27-2022 11:00 AM. Speakers...

Neutral

International Rett Syndrome Foundation, Rett Sy...

2022-04-25 11:00:00

International Rett Syndrome Foundation, Rett Syndrome Scientific Symposium 2022, Apr 26, 2022 through Apr 27, 2022.

Neutral

Anavex Life Sciences Corp., Annual General Meet...

2022-04-11 21:09:00

Anavex Life Sciences Corp., Annual General Meeting, May 24, 2022, at 10:00 Eastern Daylight. Agenda: To elect six members of the company's boa...

Neutral

Anavex Life Sciences Corp. - Pre Recorded Share...

2022-04-11 21:09:00

AGM 2022

Neutral

Anavex Life Sciences Corp. Presents at Needham ...

2022-04-07 11:08:00

Anavex Life Sciences Corp. Presents at Needham 21st Annual Healthcare Conference, Apr-14-2022 03:45 PM.

Neutral

B. Riley Securities, Inc., B. Riley Securities'...

2022-03-31 16:27:00

B. Riley Securities, Inc., B. Riley Securities's 2022 Virtual Neurology & Ophthalmology Conference, Apr 27, 2022 through Apr 28, 2022.

Neutral

Anavex Life Sciences Corp. Presents at Cantor F...

2022-03-28 11:00:00

Anavex Life Sciences Corp. Presents at Cantor Fitzgerald's Rare Orphan Disease Summit, Mar-30-2022 11:00 AM.

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Glo...

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami B...

Neutral

Needham & Company, LLC, Needham 21st Annual Hea...

2022-02-11 23:04:00

Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022.

Positive

Anavex Life Sciences Provides Supplemental Info...

2022-02-04 12:00:00

Anavex Life Sciences Corp. provided supplemental information on the ANAVEX®2-73 (blarcamesine) AVATAR Phase 3 trial for the treatment of adult...

Neutral

Anavex Life Sciences Corp. to Report Q1, 2022 R...

2022-02-03 12:00:00

Anavex Life Sciences Corp. announced that they will report Q1, 2022 results on Feb 09, 2022

Neutral

Anavex Life Sciences Corp., Q1 2022 Earnings Ca...

2022-02-03 12:00:00

Anavex Life Sciences Corp., Q1 2022 Earnings Call, Feb 09, 2022

Neutral

Anavex Life Sciences Corp. - Special Call

2022-02-01 20:57:00

To discuss the top-line results from the Phase 3 AVATAR clinical trial of ANAVEX®2-73 in adult patients with Rett syndrome

Positive

Anavex Life Sciences Corp. Reports Positive Top...

2022-02-01 12:00:00

Anavex Life Sciences Corp. reported positive top-line results from the Phase 3 randomized, double-blind, placebo-controlled AVATAR trial of AN...

Positive

Anavex Life Sciences Corp.(NasdaqGS:AVXL) added...

2021-12-20 00:00:00

Anavex Life Sciences Corp. has been added to NASDAQ Biotechnology Index.

Neutral

Anavex Life Sciences Corp. Presents at 4th Annu...

2021-11-29 12:00:00

Anavex Life Sciences Corp. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-02-2021 12:10 PM. Speakers: Christopher U. M...

Neutral

Anavex Life Sciences Corp. to Report Fiscal Yea...

2021-11-17 12:00:00

Anavex Life Sciences Corp. announced that they will report fiscal year 2021 results on Nov 24, 2021

Neutral

Anavex Life Sciences Corp., 2021 Earnings Call,...

2021-11-17 12:00:00

Anavex Life Sciences Corp., 2021 Earnings Call, Nov 24, 2021

Neutral

Anavex Life Sciences Corp. Presents at 4th Annu...

2021-11-10 13:45:00

Anavex Life Sciences Corp. Presents at 4th Annual ALS ONE Research Symposium, Nov-30-2021 09:40 AM.

Neutral

ALS One, 4th Annual ALS ONE Research Symposium,...

2021-11-10 13:00:00

ALS One, 4th Annual ALS ONE Research Symposium, Nov 29, 2021 through Nov 30, 2021.

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global...

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, Unit...

Positive

Anavex Life Sciences Corp. Reports Data Review ...

2021-10-13 11:00:00

Anavex Life Sciences Corp. (‘Anavex’ or the ‘Company’) announced that the Independent Data Safety Monitoring Board (DSMB) for the Company's Ph...

Neutral

Anavex Life Sciences Corp. Presents at 6th Annu...

2021-10-02 11:29:00

Anavex Life Sciences Corp. Presents at 6th Annual Dawson James Small Cap Growth Conference, Oct-21-2021 01:30 PM. Venue: Wyndham Grand Hotel, ...

Neutral

Anavex Life Sciences Corp. has filed a Shelf Re...

2021-09-24 00:00:00

Anavex Life Sciences Corp. has filed a Shelf Registration. Security Name: Common Stock

Negative

Anavex Life Sciences Corp. has filed a Follow-o...

2021-09-24 00:00:00

Anavex Life Sciences Corp. has filed a Follow-on Equity Offering in the amount of $150 million. Security Name: Common Stock Security Type:...

Neutral

Anavex Life Sciences Corp. Presents at Cantor G...

2021-09-20 11:00:00

Anavex Life Sciences Corp. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 10:40 AM. Venue: New York, United States. Speaker...

Neutral

Anavex Life Sciences Corp. Presents at H.C. Wai...

2021-09-09 10:04:00

Anavex Life Sciences Corp. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 . Venue: Lotte New York Palace Ho...

Positive

Anavex Life Sciences Announces Publication of F...

2021-08-26 11:00:00

Anavex Life Sciences Corp. announced that preclinical data of ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome were published in the peer-revi...

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCO...

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Neutral

Anavex Life Sciences Corp., Q3 2021 Earnings Ca...

2021-08-05 11:00:00

Anavex Life Sciences Corp., Q3 2021 Earnings Call, Aug 12, 2021

Neutral

Anavex Life Sciences Corp. to Report Q3, 2021 R...

2021-08-05 11:00:00

Anavex Life Sciences Corp. announced that they will report Q3, 2021 results on Aug 12, 2021

Neutral

Anavex Life Sciences Corp. Presents at BTIG Vir...

2021-08-04 11:00:00

Anavex Life Sciences Corp. Presents at BTIG Virtual Biotechnology Conference, Aug-10-2021 09:30 AM. Speakers: Christopher U. Missling, Chairma...

Neutral

Dawson James Securities, Inc., 6th Annual Dawso...

2021-07-30 21:59:00

Dawson James Securities, Inc., 6th Annual Dawson James Small Cap Growth Conference, Oct 21, 2021. Venue: Wyndham Grand Hotel, Jupiter, Florida...

Positive

Anavex Life Sciences Corp. Announces Anavex 2-7...

2021-07-29 11:00:00

Anavex Life Sciences Corp. reported new data that established ANAVEX 2-73 to be a preventive treatment in the pharmacological model of Alzheim...

Neutral

BTIG, LLC, BTIG Virtual Biotechnology Conferenc...

2021-07-01 10:09:00

BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021.

Neutral

Anavex Life Sciences Corp. has filed a Shelf Registration in the amount of $85.4 million.

2022-06-10 00:00:00

Anavex Life Sciences Corp. has filed a Shelf Registration in the amount of $85.4 million. Security Name: Common Stock Securities Offered: 10,000,000 Transaction Features: ESOP Related Offering

Neutral

BioToChina, CHBD, iDeals, ACCESS China Inc., BioAlps, Yafo Capital, Access China Biotech Forum, Jun 21, 2022 through Jun 24, 2022

2022-06-08 14:40:00

BioToChina, CHBD, iDeals, ACCESS China Inc., BioAlps, Yafo Capital, Access China Biotech Forum, Jun 21, 2022 through Jun 24, 2022.

Neutral

Anavex Life Sciences Corp. Presents at Access China Biotech Forum, Jun-22-2022 11:00 AM

2022-06-08 00:00:00

Anavex Life Sciences Corp. Presents at Access China Biotech Forum, Jun-22-2022 11:00 AM.

Neutral

Anavex Life Sciences Corp. Presents at H.C. Wainwright Global Investment Conference 2022, May-25-2022 12:00 PM

2022-05-20 04:14:00

Anavex Life Sciences Corp. Presents at H.C. Wainwright Global Investment Conference 2022, May-25-2022 12:00 PM. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.

Neutral

Anavex Life Sciences Corp. to Report Q2, 2022 Results on May 10, 2022

2022-05-03 11:00:00

Anavex Life Sciences Corp. announced that they will report Q2, 2022 results on May 10, 2022

Neutral

Anavex Life Sciences Corp., Q2 2022 Earnings Call, May 10, 2022

2022-05-03 11:00:00

Anavex Life Sciences Corp., Q2 2022 Earnings Call, May 10, 2022

Neutral

Anavex Life Sciences Corp. Presents at Rett Syndrome Scientific Symposium 2022, Apr-26-2022

2022-04-27 00:00:00

Anavex Life Sciences Corp. Presents at Rett Syndrome Scientific Symposium 2022, Apr-26-2022 . Speakers: Walter E. Kaufmann, Chief Scientific Officer.

Neutral

Anavex Life Sciences Corp. Presents at B. Riley Securities's 2022 Virtual Neurology & Ophthalmology Conference, Apr-27-2022 11:00 AM

2022-04-26 11:00:00

Anavex Life Sciences Corp. Presents at B. Riley Securities's 2022 Virtual Neurology & Ophthalmology Conference, Apr-27-2022 11:00 AM. Speakers: Christopher U. Missling, Chairman, President, CEO & Secretary.

Neutral

International Rett Syndrome Foundation, Rett Syndrome Scientific Symposium 2022, Apr 26, 2022 through Apr 27, 2022

2022-04-25 11:00:00

International Rett Syndrome Foundation, Rett Syndrome Scientific Symposium 2022, Apr 26, 2022 through Apr 27, 2022.

Neutral

Anavex Life Sciences Corp., Annual General Meeting, May 24, 2022

2022-04-11 21:09:00

Anavex Life Sciences Corp., Annual General Meeting, May 24, 2022, at 10:00 Eastern Daylight. Agenda: To elect six members of the company's board, each to hold office until the next annual meeting of stockholders or until such director’s successor shall have been duly elected and qualified; to ratify the appointment of BDO USA, LLP as the company’s independent registered public accounting firm;and other subject matters.

Neutral

Anavex Life Sciences Corp. - Pre Recorded Shareholder/Analyst Call

2022-04-11 21:09:00

AGM 2022

Neutral

Anavex Life Sciences Corp. Presents at Needham 21st Annual Healthcare Conference, Apr-14-2022 03:45 PM

2022-04-07 11:08:00

Anavex Life Sciences Corp. Presents at Needham 21st Annual Healthcare Conference, Apr-14-2022 03:45 PM.

Neutral

B. Riley Securities, Inc., B. Riley Securities's 2022 Virtual Neurology & Ophthalmology Conference, Apr 27, 2022 through Apr 28, 2022

2022-03-31 16:27:00

B. Riley Securities, Inc., B. Riley Securities's 2022 Virtual Neurology & Ophthalmology Conference, Apr 27, 2022 through Apr 28, 2022.

Neutral

Anavex Life Sciences Corp. Presents at Cantor Fitzgerald's Rare Orphan Disease Summit, Mar-30-2022 11:00 AM

2022-03-28 11:00:00

Anavex Life Sciences Corp. Presents at Cantor Fitzgerald's Rare Orphan Disease Summit, Mar-30-2022 11:00 AM.

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.

Neutral

Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022

2022-02-11 23:04:00

Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022.

Positive

Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial for the Treatment of Adult Patients with Rett Syndrome

2022-02-04 12:00:00

Anavex Life Sciences Corp. provided supplemental information on the ANAVEX®2-73 (blarcamesine) AVATAR Phase 3 trial for the treatment of adult patients with Rett syndrome. Following the successful completion of U.S. Phase 2 Rett syndrome study (ANAVEX®2-73-RS-001) as announced in December 2020, and the knowledge gained from it, the AVATAR study (ANAVEX®2-73-RS-002) appropriately updated endpoints according to ICH guidelines were approved by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and in Australia by the Human Research Ethics Committees (HREC), where the AVATAR study was conducted. Subsequently the AVATAR study was updated from a Phase 2 to a Phase 3 study. The January 2022 update to the trial description in ‘clinicaltrials.gov’ was not a real-time communication and may have given the wrong impression of a late change of trial endpoints /phase of the study, which is not the case. Based on the results of the AVATAR Phase 3 study (ANAVEX®2-73-RS-002) and the prior successful U.S. Phase 2 (ANAVEX®2-73-RS-001) study in adult patients with Rett syndrome, Anavex is planning to meet with the FDA to discuss the approval pathway. There are no FDA-approved drugs for Rett syndrome. ANAVEX®2-73 has Fast Track designation, Rare Pediatric Disease designation and Orphan Drug designation from the FDA for the treatment of Rett syndrome.

Neutral

Anavex Life Sciences Corp. to Report Q1, 2022 Results on Feb 09, 2022

2022-02-03 12:00:00

Anavex Life Sciences Corp. announced that they will report Q1, 2022 results on Feb 09, 2022

Neutral

Anavex Life Sciences Corp., Q1 2022 Earnings Call, Feb 09, 2022

2022-02-03 12:00:00

Anavex Life Sciences Corp., Q1 2022 Earnings Call, Feb 09, 2022

Neutral

Anavex Life Sciences Corp. - Special Call

2022-02-01 20:57:00

To discuss the top-line results from the Phase 3 AVATAR clinical trial of ANAVEX®2-73 in adult patients with Rett syndrome

Positive

Anavex Life Sciences Corp. Reports Positive Top-Line Results from the Phase 3 Randomized, Double-Blind, Placebo-Controlled AVATAR trial of ANAVEX®2-73

2022-02-01 12:00:00

Anavex Life Sciences Corp. reported positive top-line results from the Phase 3 randomized, double-blind, placebo-controlled AVATAR trial of ANAVEX®2-73 (blarcamesine) in adult female patients with Rett syndrome and demonstrated a statistically significant improvement over placebo for the primary efficacy endpoint as well as for all the secondary efficacy endpoints. Convenient once daily oral liquid doses of up to 30mg ANAVEX®2-73 was well tolerated with very good medication compliance. Rett syndrome is a chronic CNS disease caused by a spontaneous mutation of one gene, MECP2. ANAVEX®2-73 activates the sigma-1 receptor (SIGMAR1). Data suggests that activation of SIGMAR1 results in the restoration of homeostatic function within the body and is pivotal to restoring neural cell balance and the promotion of neuroplasticity. Recent independent findings strengthen the understanding of the beneficial effects of SIGMAR1 activation as a compensatory mechanism to chronic CNS diseases. In the primary endpoint, RSBQ AUC, ANAVEX®2-73 induced a statistically significant and clinical meaningful improvement in 72.2% of patients as compared to 38.5% on placebo; (p = 0.037) with a Cohen’s d effect size of 1.91 (very large). The secondary efficacy endpoints also demonstrated statistically significant and clinical meaningful improvements. For the ADAMS, a measure of emotional behavior symptoms, a significantly higher proportion of ANAVEX®2-73 treated adult patients with Rett syndrome (52.9%) than placebo-treated patients (8.3%) showed improvement (p = 0.010), which corresponded to a Cohen’s d effect size of 0.609 (large). For the CGI-I, more patients achieved clinically meaningful CGI-I response over the treatment duration in the ANAVEX®2-73-treated group (72.2%) than in the placebo group (38.5%); (p = 0.037) with a Cohen’s d effect size of 1.91 (very large). Based on the results in this Phase 3 study (ANAVEX®2-73-RS-002)3 and the prior successful U.S. Phase 2 (ANAVEX®2-73-RS-001)4 study in adult patients with Rett syndrome, Anavex is planning to meet with FDA to discuss the approval pathway. There are no FDA-approved drugs for Rett syndrome. ANAVEX®2-73 has Fast Track designation, Rare Pediatric Disease designation and Orphan Drug designation from the FDA for the treatment of Rett syndrome and may be considered for accelerated approval. The placebo-controlled EXCELLENCE Phase 2/3 pediatric Rett syndrome study (ANAVEX®2-73-RS-003)5 is currently ongoing and is evaluating ANAVEX®2-73 for Rett syndrome patients ages 5 to 17. Summary of Top-line ANAVEX®2-73 (blarcamesine) Placebo-Controlled Phase 3 AVATAR Rett Syndrome Trial Results: The study evaluated the efficacy and safety of ANAVEX®2-73 in 33 adult female patients diagnosed with Rett syndrome (positive MECP2 gene mutation). Effect on Rett Syndrome Symptoms: Primary (RSBQ AUC; p = 0.037) and secondary (ADAMS; p = 0.010); (CGI-I; p = 0.037) efficacy endpoints met. ANAVEX®2-73 induces a statistically significant and clinical meaningful improvement of RSBQ AUC in 72.2% of patients as compared to 38.5% on placebo; (p = 0.037). Cohen’s d effect size 1.91 (very large). Clinically meaningful and statistically significant reduction of emotional behavior symptoms (ADAMS) in ANAVEX®2-73 treated adult patients with Rett syndrome (52.9%) vs placebo (8.3%); (p = 0.010). Cohen’s d effect size 0.609 (large). Significantly more patients achieve clinically meaningful CGI-I response over the treatment duration in ANAVEX®2-73-treated group (72.2%) as compared with placebo (38.5%); (p = 0.037). Cohen’s d effect size 1.91 (very large). Efficacy endpoints demonstrated statistically significant and clinically meaningful reductions in Rett syndrome symptoms with related changes in potential biomarkers of disease pathology: GABA was significantly increased (p = 0.0205). L-Alpha-aminoadipic acid (L-AAA) was significantly decreased (p = 0.0392). Confirmed dose-response: RS-001 study 5mg ANAVEX®2-73 dose RSBQ AUC Cohen’s d (effect size) of 0.517. RS-002 study 30mg ANAVEX®2-73 dose RSBQ AUC Cohen’s d (effect size) of 1.91. ANAVEX®2-73 demonstrated dose-related significant improvement in overall Quality of Life (QoL) measured with CHQ-PF50 (p = 0.030).

Positive

Anavex Life Sciences Corp.(NasdaqGS:AVXL) added to NASDAQ Biotechnology Index

2021-12-20 00:00:00

Anavex Life Sciences Corp. has been added to NASDAQ Biotechnology Index.

Neutral

Anavex Life Sciences Corp. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-02-2021 12:10 PM

2021-11-29 12:00:00

Anavex Life Sciences Corp. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-02-2021 12:10 PM. Speakers: Christopher U. Missling, Chairman, President, CEO & Secretary.

Neutral

Anavex Life Sciences Corp. to Report Fiscal Year 2021 Results on Nov 24, 2021

2021-11-17 12:00:00

Anavex Life Sciences Corp. announced that they will report fiscal year 2021 results on Nov 24, 2021

Neutral

Anavex Life Sciences Corp., 2021 Earnings Call, Nov 24, 2021

2021-11-17 12:00:00

Anavex Life Sciences Corp., 2021 Earnings Call, Nov 24, 2021

Neutral

Anavex Life Sciences Corp. Presents at 4th Annual ALS ONE Research Symposium, Nov-30-2021 09:40 AM

2021-11-10 13:45:00

Anavex Life Sciences Corp. Presents at 4th Annual ALS ONE Research Symposium, Nov-30-2021 09:40 AM.

Neutral

ALS One, 4th Annual ALS ONE Research Symposium, Nov 29, 2021 through Nov 30, 2021

2021-11-10 13:00:00

ALS One, 4th Annual ALS ONE Research Symposium, Nov 29, 2021 through Nov 30, 2021.

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, United States.

Positive

Anavex Life Sciences Corp. Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease

2021-10-13 11:00:00

Anavex Life Sciences Corp. (‘Anavex’ or the ‘Company’) announced that the Independent Data Safety Monitoring Board (DSMB) for the Company's Phase 2b/3 Alzheimer’s disease study of its investigational compound ANAVEX®2-73 (blarcamesine) has completed its recent pre-planned review of the preliminary Phase 2b/3 study data. As specified in the protocol, the DSMB reviewed the interim safety data for the ANAVEX®2-73 Phase 2b/3 Alzheimer’s disease clinical study ANAVEX®2-73-AD-004 and its Open Label Extension (OLE) ANAVEX®2-73-AD-EP-004 ATTENTION-AD study. Upon review of the interim safety data, the DSMB made the following recommendation: The DSMB recommendation is to continue the studies without modification. DSMBs are committees commonly used in clinical trials to protect the interests of the patients and the integrity of the study data in ongoing trials. ANAVEX®2-73 activates the sigma-1 receptor (SIGMAR1). Data suggests that activation of SIGMAR1 results in the restoration of complete housekeeping function within the body and is pivotal to restoring neural cell homeostasis and promoting neuroplasticity. PET scan data previously confirmed dose-dependent target engagement of SIGMAR1 with ANAVEX®2-73. The placebo-controlled 509-patient Phase 2b/3 ANAVEX®2-73 clinical study in patients with Alzheimer's disease achieved full enrollment and includes prespecified SIGMAR1 gene expression as endpoints using ADAS-Cog (cognition) and ADCS-ADL (activities of daily living and function) as primary endpoints. The Company anticipates topline data in the second half of 2022. Anavex Life Sciences’ product portfolio includes small drug molecule lead candidate ANAVEX®2-73 for the treatment of Alzheimer’s disease, Parkinson’s disease and Rett syndrome. ANAVEX®2-73-AD-004 clinical study is a Phase 2b/3 double-blind, randomized, placebo-controlled, 48-week safety and efficacy trial of ANAVEX®2-73 for the treatment of early Alzheimer’s disease. The Phase 2b/3 study enrolled 509 patients, randomized 1:1:1 to two different ANAVEX®2-73 doses or placebo. The ANAVEX®2-73 Phase 2b/3 study design includes genomic precision medicine biomarkers identified in the previous ANAVEX®2-73 Phase 2a study (ANAVEX2-73-002, NCT02244541). Primary and secondary endpoints will assess safety and both cognitive and functional efficacy, measured through ADAS-Cog, ADCS-ADL and CDR-SB. ANAVEX®2-73 Phase 2a Alzheimer’s disease study previously demonstrated dose dependent improvement in exploratory endpoints of cognition (MMSE) and function (ADCS-ADL).ANAVEX®2-73-AD-EP-004 is the 96-week open label extension of the placebo-controlled Phase 2b/3 ANAVEX®2-73 study.

Neutral

Anavex Life Sciences Corp. Presents at 6th Annual Dawson James Small Cap Growth Conference, Oct-21-2021 01:30 PM

2021-10-02 11:29:00

Anavex Life Sciences Corp. Presents at 6th Annual Dawson James Small Cap Growth Conference, Oct-21-2021 01:30 PM. Venue: Wyndham Grand Hotel, Jupiter, Florida, United States. Speakers: Christopher U. Missling, Chairman, President, CEO & Secretary.

Neutral

Anavex Life Sciences Corp. has filed a Shelf Registration.

2021-09-24 00:00:00

Anavex Life Sciences Corp. has filed a Shelf Registration. Security Name: Common Stock

Negative

Anavex Life Sciences Corp. has filed a Follow-on Equity Offering in the amount of $150 million.

2021-09-24 00:00:00

Anavex Life Sciences Corp. has filed a Follow-on Equity Offering in the amount of $150 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering

Neutral

Anavex Life Sciences Corp. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 10:40 AM

2021-09-20 11:00:00

Anavex Life Sciences Corp. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 10:40 AM. Venue: New York, United States. Speakers: Christopher U. Missling, Chairman, President, CEO & Secretary.

Neutral

Anavex Life Sciences Corp. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021

2021-09-09 10:04:00

Anavex Life Sciences Corp. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 . Venue: Lotte New York Palace Hotel, New York City, New York, United States. Speakers: Christopher U. Missling, Chairman, President, CEO & Secretary.

Positive

Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Autism)

2021-08-26 11:00:00

Anavex Life Sciences Corp. announced that preclinical data of ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome were published in the peer-reviewed journal, Scientific Reports. Fragile X Syndrome (FXS) is the most common form of inherited intellectual disability and the most frequent single gene cause of autism spectrum disorder with an estimated population of approximately 62,500 in the US and 1,088,500 worldwide.1 At present, there is no approved treatment for Fragile X Syndrome. The study evaluated doses of ANAVEX®2-73 in Fmr1 knockout (KO) mice, a validated animal model for the disease, which resulted in the reversal of hyperactivity and restoration of associative learning as well as reduction in anxiety-like and perseverative behaviors. Positron emission tomography (PET) and ex vivo autoradiographic studies, using the highly selective SIGMAR1 PET ligand [18F]FTC-146, demonstrated ANAVEX®2-73’s dose dependent receptor occupancy. Additionally, ANAVEX®2-73 also restored pAkt and BDNF levels in the hippocampus, which are signaling pathways particularly affected in Fragile X Syndrome. ANAVEX®2-73 also showed a good safety profile. The study, “Effects of the Sigma-1 Receptor Agonist Blarcamesine in a Murine Model of Fragile X Syndrome: Neurobehavioral Phenotypes and Receptor Occupancy,” is the basis for a Phase 2/3 ANAVEX®2-73 study in Fragile X Syndrome. The fact that the investigation involved chronic administration, as opposed to acute dosing, provides additional evidence in favor of the clinical use of ANAVEX®2-73. Since the behavioral paradigms reflect the involvement of multiple cortical and subcortical regions, their marked improvement by ANAVEX®2-73 suggest widespread activation of SIGMAR1 by the drug and modulation of multiple neural pathways. Indeed, the observation of normalization of pAkt and BDNF levels after ANAVEX®2-73 administration, in a brain region critical for cognition and behavior, is also a finding with important implications for Fragile X Syndrome and other synaptic disorders. Altogether, these neurobehavioral, biochemical, and imaging data demonstrate that corresponding doses of ANAVEX®2-73 that yield measurable receptor occupancy are effective for substantially correcting key synaptic and behavioral phenotypes in Fmr1 KO mice. The data also suggest that these positive effects are mediated by SIGMAR1 activation in multiple brain regions, where ANAVEX®2-73 binds to the receptor in a dose-dependent and genotype-independent manner. The study was supported by the FRAXA Research Foundation.

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Neutral

Anavex Life Sciences Corp., Q3 2021 Earnings Call, Aug 12, 2021

2021-08-05 11:00:00

Anavex Life Sciences Corp., Q3 2021 Earnings Call, Aug 12, 2021

Neutral

Anavex Life Sciences Corp. to Report Q3, 2021 Results on Aug 12, 2021

2021-08-05 11:00:00

Anavex Life Sciences Corp. announced that they will report Q3, 2021 results on Aug 12, 2021

Neutral

Anavex Life Sciences Corp. Presents at BTIG Virtual Biotechnology Conference, Aug-10-2021 09:30 AM

2021-08-04 11:00:00

Anavex Life Sciences Corp. Presents at BTIG Virtual Biotechnology Conference, Aug-10-2021 09:30 AM. Speakers: Christopher U. Missling, Chairman, President, CEO & Secretary, Nell Rebowe, Director of Business Development.

Neutral

Dawson James Securities, Inc., 6th Annual Dawson James Small Cap Growth Conference, Oct 21, 2021

2021-07-30 21:59:00

Dawson James Securities, Inc., 6th Annual Dawson James Small Cap Growth Conference, Oct 21, 2021. Venue: Wyndham Grand Hotel, Jupiter, Florida, United States.

Positive

Anavex Life Sciences Corp. Announces Anavex 2-73 (Blarcamesine) Significantly Prevented Aß (Abeta)-Induced Cognitive Deficits with Confirmes Significant Biomarker-Response in Animal Model of Alzheimer’S Disease

2021-07-29 11:00:00

Anavex Life Sciences Corp. reported new data that established ANAVEX 2-73 to be a preventive treatment in the pharmacological model of Alzheimer's disease (AD). Pre-treatment with ANAVEX2-73, repeated once daily for one week before the Aß (Abeta) challenge was protective in the Aß25-35 peptide model of Alzheimer’s disease in mice. ANAVEX 2-73 significantly and dose-dependently prevented Aß25-35-induced biomarker-correlated cognitive impairments, which were assessed one week after the Aß (Abeta) insult during which no further ANAVEX 2-73 treatment took place. ANAVEX 2-73 activates the sigma-1 receptor (SIGMAR). Data suggests that activation of SIGMAR1 results in the restoration of complete housekeeping function within the body and is pivotal to restoring neural cell homeostasis and promoting neuroplasticity.1 SIGMAR1 also promotes autophagy and results in the degradation of amyloid-beta precursor protein (APP) thereby inhibiting Aß production. Data from this study will be submitted later this year for presentation at a scientific medical meeting. Previously, a publication in Neuropharmacology noted that in a clinical study (ANAVEX2-73-002) of Alzheimer’s disease patients, 57 weeks of oral once daily ANAVEX 2-73 treatment showed patients improved cognition scores by +2.0 points on MMSE, a 9% mean improvement from baseline to 57 weeks, corresponding to a calculated ADAS-Cog score change of -3.4 (improvement). In these same patients ANAVEX 2-73 also improved ADCS-ADL, by +4.9 points, a 7% mean improvement from baseline to 57 weeks. An extension of the published study (ANAVEX2-73-003) demonstrated that for the same patients at week 70 MMSE scores improved by +3.0, a 14% improvement from baseline, corresponding to a calculated ADAS-Cog score change of -5.1 (improvement). In these same patients, ANAVEX2-73 also improved ADCS-ADL, by +6.0 points, an 8% mean improvement from baseline to 70 weeks. The mean MMSE and ADCS-ADL baseline scores for these patients in this study were 22.3 and 71.1, respectively. This data seems to be consistent with the effect of ANAVEX2-73 on cognition assessed in the recently completed placebo-controlled Phase 2 study of 132 patients with Parkinson’s disease dementia (ANAVEX2-73-PDD-001) with once-daily administration of oral 30 mg ANAVEX2-73, 50 mg ANAVEX 2-73 and placebo for 14 weeks. The observed statistically significant improvement of CDR system Episodic Memory of +42.22 between 50 mg ANAVEX2-73 and placebo was also dose-dependent (p = 0.003).6 CDR system Episodic Memory has been shown to be highly correlated (70%) with the ADAS-Cog score (r = 0.7).7 The calculated corresponding ADAS-Cog mean change from baseline score is -1.9 (improvement) for patients in the 50 mg dose group, an 8% mean improvement from baseline to 14 weeks. The difference between the ANAVEX 2-73 group and the placebo group in the change from baseline at 14 weeks was a 4.0-point improvement of calculated corresponding ADAS-Cog score (p = 0.015). The Company recently announced that it has exceeded its enrollment target for the ANAVEX 2-73 (blarcamesine) double-blind, placebo-controlled late-stage Phase 2b/3 study (ANAVEX2-73-004) in Alzheimer’s disease. Anavex Life Sciences’ product portfolio platform includes orally available small molecule drug lead candidate ANAVEX2-73 for the treatment of Alzheimer’s disease, Parkinson’s disease and Rett syndrome and ANAVEX3-71 for frontotemporal dementia.

Neutral

BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021

2021-07-01 10:09:00

BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021.

Fundamental Summary

Anavex Life Sciences published its Q1 report on 2022-05-10 with positive results, but no significant factors particularly remarkable relative to its peers. It is highly likely that it will be mostly tethered to market performance and sector movements for the near term. Overall, Anavex Life Sciences's growth and income factors are trending positively, and we, therefore, give Anavex Life Sciences an overall grade of 67 and a HOLD recommendation.

Anavex Life Sciences reported earnings results for the second quarter and six months ended March 31, 2022. For the second quarter, the company reported net loss was USD 10.44 million compared to USD 8.16 million a year ago. Basic loss per share from continuing operations was USD 0.14 compared to USD 0.12 a year ago. Diluted loss per share from continuing operations was USD 0.14 compared to USD 0.12 a year ago.For the six months, net loss was USD 21.32 million compared to USD 16.01 million a year ago. Basic loss per share from continuing operations was USD 0.28 compared to USD 0.24 a year ago. Diluted loss per share from continuing operations was USD 0.28 compared to USD 0.24 a year ago.

Business Description

Anavex Life Sciences, a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer’s disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson’s disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company’s drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson’s, and Alzheimer’s diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Sector Overview

Anavex Life Sciences is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Anavex Life Sciences's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 160.3 2.2% 67
Liabilities 8.1 -23.3% 50
Price to Book 5.3 -41.3% 66
Cash & Equivalents 153.3 1.5% 75
Equity 152.2 4.0% 50
EBITDA -13.7 0.0% 69
Parameter Value Change Score
Return on Equity -37.9 10.8% 60
Net Cashflow 77.5 -25.3% 69
Capital Expenditure -0.0 0.0% 74
Free Cashflow -0.4 -6.1% 63

* All values are TTM

The below chart reflects Anavex Life Sciences's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Anavex Life Sciences's peer average final assessment score stands on 65.0, Anavex Life Sciences's score is 67.

  •  AVXL
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amgen Inc. 130.1B 69 78 81
Hold
77
77 0 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 1 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 3 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 4 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 5 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 7 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 8 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 9 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 10 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 11 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 12 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 13 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 15 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 16 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 17 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 18 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 19 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 20 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 22 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 23 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 24 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 26 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 28 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 29 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 30 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 31 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 32 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 33 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 34 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 36 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 37 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 38 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 39 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 40 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 41 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 42 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 43 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 45 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 46 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 47 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 48 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 49 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 50 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 51 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 52 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 53 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 54 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 55 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 56 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 57 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 58 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 59 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 60 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 61 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 62 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 63 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 64 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 65 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 66 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 67 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 68 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 69 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 70 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 73 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 74 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 75 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 77 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 78 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 79 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 80 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 81 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 82 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 83 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 84 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 85 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 86 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 92 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 93 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Anavex Life Sciences's stock is now priced above its 50-day, but below its 5-day and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the medium-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Anavex Life Sciences's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 57.

Bearish 57
Close Price 9.91
52W Low 7.31
52W High 25.75
5D MA 10.02
50D MA 8.97
200D MA 13.98
MACD 0.24
RSI 12.81
STOCH 81.44

Balance Sheet Analysis

Overall, Anavex Life Sciences's critical balance sheet metrics appear to signal strong support and a high likelihood of positive growth going forward. Anavex Life Sciences reported a positive trendline in their cash and cash equivalents metrics. Specifically, they reported that cash and cash equivalents were 153.3, representing 1.5% change from the last report. Its impressive cash and cash equivalents metrics should support upward pressure on its's stock price. The company's cash and cash equivalents movement, therefore, received a grade of 75. Also, The company's assets section could set high expectations for Anavex Life Sciences's future attractiveness, as they went to 160.3, which is a 2.2% change from the last period. This performance is interesting in comparison to its peers and competitors. Therefore, its asset component earned a score of 67. At the same time, one critical balance sheet metric, Liabilities, was notably weak. In terms of liabilities, Anavex Life Sciences published uninspiring results. Their reported liabilities were 8.1, representing a -23.3% change from the previous report. Anavex Life Sciences's liabilities changes appear mediocre compared to their peers. Contextually, they convey that management finds balancing asset growth, resource allocation, and liabilities challenging. Its liabilities movement component, therefore, received a grade of 50. Similarly, because their management is doing an excellent job managing these critical metrics, the balance sheet was given a score of 61.

Parameter Value Change Score
Assets 160.3 2.2% 67
Liabilities 8.1 -23.3% 50
Price to Book 5.3 -41.3% 66
Cash & Equivalents 153.3 1.5% 75
Equity 152.2 4.0% 50
* All values are TTM

The below chart describes Anavex Life Sciences's performance as reflected on its balance sheet with respect to its peers. While Anavex Life Sciences received a balance sheet score of 61, the average of its peers stands on 65.0.

  •  AVXL
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amgen Inc. 130.1B 72 68 86 53 62 69 0 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 1 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 3 1
BioNTech SE 34.0B 75 69 64 97 73 75 4 1
Seagen Inc. 32.9B 59 68 55 43 66 61 5 1
Biogen Inc. 29.7B 57 72 92 50 76 76 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 7 1
Incyte Corporation 16.8B 71 72 95 82 79 83 8 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 9 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 10 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 11 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 12 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 13 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 14 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 15 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 16 1
Alkermes plc 5.0B 63 66 46 54 71 62 17 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 18 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 19 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 20 1
Natera, Inc. 3.6B 73 65 43 95 42 54 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 22 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 23 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 24 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 26 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 28 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 29 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 30 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 31 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 32 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 33 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 34 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 36 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 37 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 38 1
Geron Corporation 566.2M 69 72 37 59 62 60 39 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 40 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 41 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 42 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 43 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 45 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 46 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 47 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 48 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 49 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 50 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 51 1
CureVac N.V. 2.6B 49 64 75 52 52 57 52 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 53 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 54 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 55 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 56 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 57 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 58 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 59 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 60 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 61 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 62 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 63 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 64 1
CareDx, Inc 1.2B 54 67 52 39 51 52 65 1
Vericel Corporation 1.1B 51 65 56 53 61 57 66 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 67 1
MannKind Corporation 957.2M 79 59 50 40 64 57 68 1
Merus N.V. 941.6M 59 68 50 83 81 70 69 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 70 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 73 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 74 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 75 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 76 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 77 1
Immatics N.V. 538.7M 56 70 84 95 73 76 78 1
Agenus Inc. 520.5M 73 62 37 55 60 54 79 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 80 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 81 1
Affimed N.V. 415.0M 56 66 63 56 47 54 82 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 83 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 84 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 85 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 86 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
AC Immune SA 299.8M 84 64 47 53 75 68 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 92 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 93 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Anavex Life Sciences appears likely to maintain its strong income statement metrics, especially EBITDA. Anavex Life Sciences's management was effective in improving its EBIDTA, which now sits at -13.7 and represents a 0.0% change from the last reporting period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. Its EBITDA metrics highlight an impressive overall financial performance, which is expected to continue moving forward. The company's EBITDA movement, therefore, received a grade of 69. That said, one metric, Return Factors, stood out as strongly negative. In this filing, Anavex Life Sciences reported a return on equity (ROE) ratio of -37.9, which represents a growth of 10.8%. This metric might have a 3.6 percent impact on companies in the same industry and with the same market capitalization. The company's return factor metrics return on equity and return on assets are even more concerning when compared to their peers. Consequently, their return factors received a grade of 60. their income statement received an overall score of 75.

Parameter Value Change Score
EBITDA -13.7 0.0% 69
Return on Equity -37.9 10.8% 60
* All values are TTM

The below chart describes Anavex Life Sciences's performance as reflected on its income statement with respect to its peers. While Anavex Life Sciences received a income statement score of 75 , the average of its peers stands on 67.0.

  •  AVXL
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amgen Inc. 130.1B 74 75 64 78 0 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 1 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 3 1
BioNTech SE 34.0B 41 89 75 79 4 1
Seagen Inc. 32.9B 54 65 70 62 5 1
Biogen Inc. 29.7B 90 57 73 70 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 7 1
Incyte Corporation 16.8B 59 77 60 73 8 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 9 1
United Therapeutics Corporation 10.6B 57 91 54 82 10 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 11 1
Exelixis, Inc. 6.7B 54 91 54 81 12 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 13 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 15 1
Ascendis Pharma A/S 5.2B 38 68 46 54 16 1
Alkermes plc 5.0B 69 55 81 62 17 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 18 1
Novavax, Inc. 4.0B 41 89 54 75 19 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 20 1
Natera, Inc. 3.6B 52 51 78 52 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 22 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 23 1
Insmed Incorporated 2.4B 51 58 73 57 24 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 26 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 28 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 29 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 30 1
IVERIC bio, Inc. 1.1B 84 58 79 70 31 1
FibroGen, Inc. 1.0B 48 74 63 67 32 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 33 1
ImmunoGen, Inc. 946.1M 40 73 71 64 34 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 36 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 37 1
AnaptysBio, Inc. 586.3M 97 50 77 68 38 1
Geron Corporation 566.2M 89 67 73 78 39 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 40 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 41 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 42 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 43 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 45 1
Precigen, Inc. 299.1M 57 87 59 79 46 1
bluebird bio, Inc. 288.7M 99 91 61 96 47 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 48 1
MacroGenics, Inc. 184.6M 95 56 74 71 49 1
Exact Sciences Corporation 7.2B 57 67 54 62 50 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 51 1
CureVac N.V. 2.6B 45 83 71 74 52 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 53 1
Abgenix Inc. 2.1B 47 47 47 47 54 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 55 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 56 1
Xencor, Inc. 1.6B 42 94 52 79 57 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 58 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 59 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 60 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 61 1
Veracyte, Inc. 1.4B 45 63 57 55 62 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 63 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 64 1
CareDx, Inc 1.2B 61 44 82 50 65 1
Vericel Corporation 1.1B 76 44 82 56 66 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 67 1
MannKind Corporation 957.2M 95 48 56 61 68 1
Merus N.V. 941.6M 48 60 59 54 69 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 70 1
Amarin Corporation plc 734.5M 95 44 82 63 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 72 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 73 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 74 1
CTI BioPharma Corp. 603.6M 84 50 62 59 75 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 77 1
Immatics N.V. 538.7M 37 93 53 77 78 1
Agenus Inc. 520.5M 57 83 45 74 79 1
Radius Health, Inc. 499.8M 94 71 68 82 80 1
Vaxart, Inc. 440.0M 99 51 72 68 81 1
Affimed N.V. 415.0M 95 49 75 66 82 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 83 1
MiMedx Group, Inc. 391.5M 87 43 83 59 84 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 85 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 86 1
Zymeworks Inc. 324.7M 58 53 77 56 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
AC Immune SA 299.8M 83 61 65 70 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 92 1
Chimerix, Inc. 178.4M 99 50 62 65 93 1
DermTech, Inc. 165.3M 49 48 78 52 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Capex and Net Cash Flow stand out as the most significant drivers of Anavex Life Sciences's cash flow's strength. Anavex Life Sciences's management did a great job this period managing its capital expenditure (CapEx). In terms of the raw numbers, CapEx was reported as -0.0, which represents a 0.0% change from the last period. The company appears to be headed in the right direction regarding resource allocation, exhibiting prudent capital expenditure growth compared to its peers. Therefore, its CapEx movement component earned a score of 74. Also, Anavex Life Sciences's strong net cash flow numbers, which were 77.5 in this filing, showed a -25.3% change from the last period. The company is headed in the right direction regarding business priorities, exhibiting prudent net cash flow management and growth. Hence, its net cash flow earned a score of 69. That said, one metric, Free Cash flow, stood out as strongly negative. Free cash flow numbers published by Anavex Life Sciences were -0.4, which was a -6.1% change from the previous filing. Companies in the same sector and market capitalization will usually be affected by up to 2.6 percent by this parameter. Their free cash flow situation is more concerning relative to their peers and competitors. Disappointing results in free cash flow often lead to negative pressure in stock prices, so we rated their free cash flow with a score of 63. Consequently, its cash flow earned a score of 72.

Parameter Value Change Score
Net Cashflow 77.5 -25.3% 69
Capital Expenditure -0.0 0.0% 74
Free Cashflow -0.4 -6.1% 63
* All values are TTM

The below chart describes Anavex Life Sciences's performance as reflected on its cash flow with respect to its peers. While Anavex Life Sciences received a cash flow score of 72, the average of its peers stands on 69.0.

  •  AVXL
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amgen Inc. 130.1B 80 74 67 74 81 0 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 1 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 3 1
BioNTech SE 34.0B 73 97 50 52 72 4 1
Seagen Inc. 32.9B 53 53 50 87 58 5 1
Biogen Inc. 29.7B 58 54 90 73 66 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 7 1
Incyte Corporation 16.8B 78 79 92 74 84 8 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 9 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 10 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 11 1
Exelixis, Inc. 6.7B 79 90 89 83 87 12 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 13 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 14 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 15 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 16 1
Alkermes plc 5.0B 89 95 76 80 92 17 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 18 1
Novavax, Inc. 4.0B 62 38 63 54 60 19 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 20 1
Natera, Inc. 3.6B 52 54 56 84 58 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 22 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 23 1
Insmed Incorporated 2.4B 79 80 61 89 82 24 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 26 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 28 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 29 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 30 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 31 1
FibroGen, Inc. 1.0B 86 74 48 87 84 32 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 33 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 34 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 36 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 37 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 38 1
Geron Corporation 566.2M 78 68 49 81 77 39 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 40 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 41 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 42 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 43 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 45 1
Precigen, Inc. 299.1M 82 75 37 85 74 46 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 47 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 48 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 49 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 50 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 51 1
CureVac N.V. 2.6B 87 80 90 70 90 52 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 53 1
Abgenix Inc. 2.1B 66 53 45 59 58 54 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 55 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 56 1
Xencor, Inc. 1.6B 96 95 70 95 98 57 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 58 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 59 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 60 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 61 1
Veracyte, Inc. 1.4B 90 95 46 46 82 62 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 63 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 64 1
CareDx, Inc 1.2B 98 84 40 50 86 65 1
Vericel Corporation 1.1B 64 46 59 73 65 66 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 67 1
MannKind Corporation 957.2M 77 56 43 37 66 68 1
Merus N.V. 941.6M 70 71 74 53 71 69 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 70 1
Amarin Corporation plc 734.5M 52 40 74 55 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 72 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 73 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 74 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 75 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 76 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 77 1
Immatics N.V. 538.7M 82 95 56 99 86 78 1
Agenus Inc. 520.5M 57 43 52 77 58 79 1
Radius Health, Inc. 499.8M 64 40 37 56 57 80 1
Vaxart, Inc. 440.0M 72 56 53 38 65 81 1
Affimed N.V. 415.0M 72 57 95 43 74 82 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 83 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 84 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 85 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 86 1
Zymeworks Inc. 324.7M 52 65 45 83 57 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
AC Immune SA 299.8M 66 77 79 63 68 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 92 1
Chimerix, Inc. 178.4M 80 84 95 47 83 93 1
DermTech, Inc. 165.3M 60 51 45 86 58 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.